Evidence map›Paper›PMID 28384660›Full record

Observational studyJAMA cardiology2017

Association Between HIV Infection and the Risk of Heart Failure With Reduced Ejection Fraction and Preserved Ejection Fraction in the Antiretroviral Therapy Era: Results From the Veterans Aging Cohort Study.

Matthew S Freiberg, Chung-Chou H Chang, Melissa Skanderson, Olga V Patterson, Scott L DuVall, Cynthia A Brandt, Kaku A So-Armah, Ramachandran S Vasan, Kris Ann Oursler, John Gottdiener and 16 more

Registry-linked trialOpen access · greenAbstract readObservational Study
In one paragraph

Observational study in JAMA cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04904406 (Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection), which is not on this map. Cited by 206 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
206citing papers in PubMed, 7 pooled it
26.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04904406 phase4completednot on this mapstarted 2020, after this paper: background citation

Changes in Weight and Body Composition After Switch to Dolutegravir/Lamivudine Compared to Continued Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed HIV Infection: A Randomized Open-label Superiority Trial: AVERTAS-1

TypeinterventionalSponsorThomas BenfieldRan2020 to 2023Enrolled81ConditionsHiv, HIV Infections, HIV Cardiomyopathy, Weight Change, BodyArmsDolutegravir / Lamivudine Oral Tablet
3 · Its place in the literature

Who cites it

206 citing papers in PubMed, 7 syntheses or guidelines pooled it, 300 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Brief Report: Statin Effects on Myocardial Fibrosis Markers in People Living With HIV.Journal of acquired immune deficiency syndromes (1999) · 2018
    Trial
  13. Observational
  14. Developing machine learning models to improve cardiovascular risk prediction for people living with HIV.International journal of cardiology. Cardiovascular risk and prevention · 2026
    Article
  15. Article
  16. Diagnostic Tests for Stage B Heart Failure.Current cardiology reports · 2026
    Review
  17. Article
  18. Article
  19. The Bacterial, Viral, and Microbiome Contributions in Cardiovascular Diseases: A Narrative Review.Indian journal of community medicine : official publication of Indian Association of Preventive & Social Medicine · 2026
    Review
  20. Article

146 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors at 20 institutions in 1 country.

Matthew S FreibergDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee2Geriatric Research Education and Clinical Centers, Veterans Affairs Tennessee Valley Healthcare System, Nashville.
Chung-Chou H ChangDepartment of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Melissa SkandersonResearch Division, Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, West Haven.
Olga V PattersonDepartment of Veterans Affairs Salt Lake City Health Care System, Salt Lake City6Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.
Scott L DuVallDepartment of Veterans Affairs Salt Lake City Health Care System, Salt Lake City6Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City.
Cynthia A BrandtResearch Division, Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, West Haven7Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut.
Kaku A So-ArmahDivision of General Internal Medicine, Boston University, Boston, Massachusetts.
Ramachandran S VasanDepartment of Medicine, Boston University School of Medicine, Boston, Massachusetts.
Kris Ann OurslerDepartment of Medicine, University of Maryland School of Medicine, Baltimore11Division of Infectious Diseases, Baltimore Veterans Affairs Health Care System, Baltimore, Maryland12Division of Cardiology, Baltimore Veterans Affairs Health Care System, Baltimore, Maryland.
John GottdienerDepartment of Medicine, University of Maryland School of Medicine, Baltimore.
Stephen GottliebDepartment of Medicine, University of Maryland School of Medicine, Baltimore.
David LeafDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles.
Maria Rodriguez-BarradasDepartment of Medicine, Baylor College of Medicine, Houston, Texas15Division of Infectious Diseases, Michael E. DeBakey Veterans Affairs Medical Center, Houston, Texas.
Russell P TracyDepartment of Pathology and Laboratory Medicine, University of Vermont College of Medicine, Burlington.
Cynthia L GibertDepartment of Medicine, George Washington University School of Medicine, Washington, DC18Division of Infectious Diseases, Washington DC Veterans Affairs Medical Center, Washington, DC.
David RimlandDepartment of Medicine, Emory University School of Medicine, Atlanta, Georgia20Division of Infectious Diseases, Atlanta Veterans Affairs Medical Center, Atlanta, Georgia.
Roger J BedimoDepartment of Medicine, Veterans Affairs North Texas Health Care System, Dallas.
Sheldon T BrownDivision of Infectious Diseases, James J. Peters Veterans Affairs Medical Center, Bronx, New York23Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Matthew Bidwell GoetzDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles24Division of Infectious Diseases, Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, California.
Alberta WarnerDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles25Division of Cardiology, Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, California.
Kristina CrothersDepartment of Medicine, University of Washington School of Medicine, Seattle.
Hilary A TindleDepartment of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Charles AlcornDepartment of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
Justin M BachmannDivision of Cardiovascular Medicine, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee.
Amy C JusticeResearch Division, Veterans Affairs Connecticut Health Care System, West Haven Veterans Administration Medical Center, West Haven29Department of Medicine, Yale School of Medicine, New Haven, Connecticut.
Adeel A ButtDepartment of Medicine, Weill Cornell Medical College, New York, New York.
University of Maryland, Baltimore · USUniversity of Pittsburgh · USVA Connecticut Healthcare System · USVA Greater Los Angeles Healthcare System · USVanderbilt University · USBaylor College of Medicine · USBoston University · USCornell University · USEmory University · USGeorge Washington University · USGeriatric Research Education and Clinical Center · USIcahn School of Medicine at Mount Sinai · USUniversity of California, Los Angeles · USUniversity of Utah · USUniversity of Vermont · USUniversity of Washington · USVA Maryland Health Care System · USVA North Texas Health Care System · USVA Salt Lake City Healthcare System · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Alcohol and Multisubstance Use in the Veterans Aging Cohort StudyU01AA020790 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$7.7M
Cardiovascular Disease Mechanisms in HIV Infected and Uninfected VeteransR01HL095136 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FREIBERG, MATTHEW S, JUSTICE, AMY CAROLINE · 2008 to 2012
$5.6M
Sex Disparities in Overall Response to ART Among HIV Infected IndividualsU24AA020794 · NIAAA · YALE UNIVERSITY · PI JUSTICE, AMY CAROLINE · 2011 to 2020
$5.5M
Immune function and the risk of cvd among HIV infected and uninfected veteransR01HL125032 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI FREIBERG, MATTHEW S, TRACY, RUSSELL P · 2014 to 2017
$2.8M
Novel Mechanisms Driving Excess Atherosclerotic Cardiovascular Disease Risk in the Context of HIV: The Role of Liver InjuryK01HL134147 · NHLBI · BOSTON MEDICAL CENTER · PI SO-ARMAH, KAKU · 2016 to 2020
$620k
Effect of Exercise Training on Inflammation and Function in HIV Infected VeteransI01RX000667 · VA · SALEM VA MEDICAL CENTER · PI OURSLER, KRISANN K, RYAN, ALICE S. · 2015 to 2019
–
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS K01 HL134147NHLBI NIH HHS R01 HL095136NHLBI NIH HHS R01 HL125032NIAAA NIH HHS U01 AA020790NIAAA NIH HHS U24 AA020794RRD VA I01 RX000667
6 · The paper itself

Abstract

Importance: With improved survival, heart failure (HF) has become a major complication for individuals with human immunodeficiency virus (HIV) infection. It is unclear if this risk extends to different types of HF in the antiretroviral therapy (ART) era. Determining whether HIV infection is associated with HF with reduced ejection fraction (HFrEF), HF with preserved ejection fraction (HFpEF), or both is critical because HF types differ with respect to underlying mechanism, treatment, and prognosis. Objectives: To investigate whether HIV infection increases the risk of future HFrEF and HFpEF and to assess if this risk varies by sociodemographic and HIV-specific factors. Design, Setting, and Participants: This study evaluated 98 015 participants without baseline cardiovascular disease from the Veterans Aging Cohort Study, an observational cohort of HIV-infected veterans and uninfected veterans matched by age, sex, race/ethnicity, and clinical site, enrolled on or after April 1, 2003, and followed up through September 30, 2012. The dates of the analysis were October 2015 to November 2016. Exposure: Human immunodeficiency virus infection. Main Outcomes and Measures: Outcomes included HFpEF (EF≥50%), borderline HFpEF (EF 40%-49%), HFrEF (EF<40%), and HF of unknown type (EF missing). Results: Among 98 015 participants, the mean (SD) age at enrollment in the study was 48.3 (9.8) years, 97.0% were male, and 32.2% had HIV infection. During a median follow-up of 7.1 years, there were 2636 total HF events (34.6% were HFpEF, 15.5% were borderline HFpEF, 37.1% were HFrEF, and 12.8% were HF of unknown type). Compared with uninfected veterans, HIV-infected veterans had an increased risk of HFpEF (hazard ratio [HR], 1.21; 95% CI, 1.03-1.41), borderline HFpEF (HR, 1.37; 95% CI, 1.09-1.72), and HFrEF (HR, 1.61; 95% CI, 1.40-1.86). The risk of HFrEF was pronounced in veterans younger than 40 years at baseline (HR, 3.59; 95% CI, 1.95-6.58). Among HIV-infected veterans, time-updated HIV-1 RNA viral load of at least 500 copies/mL compared with less than 500 copies/mL was associated with an increased risk of HFrEF, and time-updated CD4 cell count less than 200 cells/mm3 compared with at least 500 cells/mm3 was associated with an increased risk of HFrEF and HFpEF. Conclusions and Relevance: Individuals who are infected with HIV have an increased risk of HFpEF, borderline HFpEF, and HFrEF compared with uninfected individuals. The increased risk of HFrEF can manifest decades earlier than would be expected in a typical uninfected population. Future research should focus on prevention, risk stratification, and identification of the mechanisms for HFrEF and HFpEF in the HIV-infected population.

Indexed as

Stroke VolumeVeteransAdultAnti-HIV AgentsCase-Control StudiesCD4 Lymphocyte CountCohort StudiesFemaleHeart FailureHIV InfectionsHumansMaleMiddle AgedProportional Hazards ModelsRisk AssessmentRisk FactorsAnti-HIV Agents

Identifiers

PMID28384660
PMCPMC5541383
OpenAlexW2604509865

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.